Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study-Reference-Cited by-全球学者库

Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study

Published:2022-02-28 Issue:1 Volume:20 Page:70-86
ISSN:1738-1088
Container-title:Clinical Psychopharmacology and Neuroscience
language:en
Short-container-title:Clin Psychopharmacol Neurosci

Author:

Jeon Hong Jin¹²³^ORCID,Ju Po-Chung⁴⁵^ORCID,Sulaiman Ahmad Hatim⁶^ORCID,Aziz Salina Abdul⁷^ORCID,Paik Jong-Woo⁸^ORCID,Tan Wilson⁹^ORCID,Bai Daisy¹⁰^ORCID,Li Cheng-Ta¹¹¹²¹³^ORCID

Affiliation:

1. Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2. Korea Psychological Autopsy Center (KPAC), Seoul, Korea

3. Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Korea

4. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

5. Department of Psychiatry, Chung Shan Medical University Hospital, Taichung, Taiwan

6. Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

7. Department of Psychiatry and Mental Health, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

8. Department of Psychiatry, Kyung Hee University College of Medicine, Seoul, Korea

9. Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore

10. Statistics & Decision Sciences, Janssen Research & Development, LLC, Shanghai, China

11. Division of Community & Rehabilitation Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan

12. Functional Neuroimaging and Brain Stimulation Lab, National Yang Ming Chiao Tung University, Taipei, Taiwan

13. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Publisher

Korean College of Neuropsychopharmacology

Subject

Pharmacology (medical),Behavioral Neuroscience,Psychiatry and Mental health

Link

http://pdf.medrang.co.kr/CPN2/2022/020/cpn020-01-07.pdf

Reference62 articles.

1. Morbidity in Depressive Disorders

2. Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options

3. Diagnosis and definition of treatment-resistant depression

4. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression

5. The Prevalence and Incidence of Treated Major Depressive Disorder among National Health Insurance Enrollees in Taiwan, 1996 to 2003

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments;Proceedings of the National Academy of Sciences;2023-11-27

2. Antidepressants enter cells, organelles, and membranes;Neuropsychopharmacology;2023-10-02

3. Antidepressants enter cells, organelles, and membranes;NEUROPSYCHOPHARMACOL;2023

4. Antidepressant discontinuation syndrome: A state-of-the-art clinical review;European Neuropsychopharmacology;2023-01

5. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review;Therapeutic Advances in Psychopharmacology;2023-01